certest biotec的viasure黄热病实时pcr检测试剂盒的性能：评估报告和监测建议

Assessment report and recommendations foruse in surveillance Performance of Certest Biotec’s VIASURE yellow fever real time PCR detection kit: assessment report andrecommendations for use in surveillance ISBN 978-92-4-011033-5 (electronic version) ISBN 978-92-4-011034-2 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestionthat WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If youadapt the work, then you must license your work under the same or equivalent Creative Commons licence. If youcreate a translation of this work, you should add the following disclaimer along with the suggested citation: “Thistranslation was not created by the World Health Organization (WHO). WHO is not responsible for the content oraccuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediationrules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.Performance of Certest Biotec’s VIASURE yellow fever real time PCR detection kit: assessmentreport and recommendations for use in surveillance. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available at https://iris.who.int/. Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders. Tosubmit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables,figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtainpermission from the copyright holder. The risk of claims resulting from infringement of any third-party-ownedcomponent in the work rests solely with the user. General disclaimers.The designations employed and the presentation of the material in this publication do notimply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country,territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted anddashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsedor recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissionsexcepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied. Theresponsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable fordamages arising from its use. Acknowledgements From the World Heath Organization (WHO): Mustafa Abdelaziz Aboualy, Amal Barakat, Anindya Bose,Maurice Demanou, Victoria Katawera, Jean-François Lemaire, Miguel Mulders, Marie-Eve Raguenaud, andJoão Paulo Toledo. From the Pan American Health Organization (PAHO)/ WHO Regional Office of the Americas: Jairo AndresMéndez-Rico. Special appreciation to Daniel Bailey, Ruth Elderfield, and Hermione ContiFrith, from the Rare andImported Pathogen Laboratory (RIPL) of the United Kingdom Health Security Agency (UKHSA) in PortonDown (United Kingdom of Great Britain and Northern Ireland) for performing the independent laboratoryperformance testing and to Ngu Njei Abanda from the Centre Pasteur du Cameroun for the kind provisionof yellow fever-negative specimen material to RIPL. World Health Organization (WHO) is also thankful toJean-Baptiste Ronat and Göran Tauber and their team from Integrated Quality Laboratory Services (IQLS)for their coordination support and expertise. This document was developed in consultation with: Individual experts including members of the Eliminate Yellow Fever Epidemics (EYE) Strategy’s advisoryLaboratory Technical Working Group (LTWG): Ngu Abanda, Ana Maria Bispo de Filippis, Cristina Domingo-Carrasco, Gamou Fall, Mary Dooshima Indyeriyo-Kaan, Zsofia Igloi, Barbara W. Johnson, John Kayiwa,Julius Lutwama, Naazneen Moolla, Felipe Naveca, Matthias Niedrig, and Huguett